CJC-1295 (No DAC)
Product Name: CJC-1295 No DAC (Modified GRF 1-29)
Format: Lyophilised peptide powder (5 mg vial)
Category: Synthetic research peptide / Growth Hormone-Releasing Hormone (GHRH) analog
Intended Use: Research/experimental peptide studies (not approved for human therapeutic use)
Overview:
CJC-1295 without DAC is a synthetic peptide analog of growth hormone-releasing hormone (GHRH) designed to stimulate the body’s own endogenous growth hormone (GH) release by mimicking the natural hypothalamic hormone signal. It is chemically modified (often referred to as Modified GRF 1–29) to enhance receptor affinity and metabolic stability compared to the native GHRH sequence.
Unlike the DAC-conjugated version of CJC-1295, this no-DAC formulation lacks the Drug Affinity Complex component. As a result, it exhibits a shorter biological half-life and produces pulsatile spikes in GH release that more closely resemble the body’s natural growth hormone secretion patterns.
Key Features:
Acts as a Growth Hormone-Releasing Hormone agonist, activating GHRH receptors in research models.
Stimulates pulsatile endogenous GH release with a relatively short duration of activity compared with DAC-modified peptides.
Typically used in scientific studies exploring endocrine signaling, growth hormone dynamics, and related molecular pathways.
Lyophilised form requires reconstitution with sterile bacteriostatic water before experimental use (in research settings only).
Administration & Handling:
Delivered via subcutaneous injection in research protocols.
Requires careful aseptic technique and proper peptide storage (cool, dry conditions away from light).
Common Research Observations:
Enhanced transient increases in GH and downstream IGF-1 levels following dosing.
Often studied in combination with other peptides (e.g., growth hormone secretagogues) to assess synergistic effects on endocrine release.
Reviews
There are no reviews yet.